209 related articles for article (PubMed ID: 22197270)
1. The neuropharmacology of prolactin secretion elicited by 3,4-methylenedioxymethamphetamine ("ecstasy"): a concurrent microdialysis and plasma analysis study.
Murnane KS; Kimmel HL; Rice KC; Howell LL
Horm Behav; 2012 Feb; 61(2):181-90. PubMed ID: 22197270
[TBL] [Abstract][Full Text] [Related]
2. Endocrine and neurochemical effects of 3,4-methylenedioxymethamphetamine and its stereoisomers in rhesus monkeys.
Murnane KS; Fantegrossi WE; Godfrey JR; Banks ML; Howell LL
J Pharmacol Exp Ther; 2010 Aug; 334(2):642-50. PubMed ID: 20466795
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological characterization of the effects of 3,4-methylenedioxymethamphetamine ("ecstasy") and its enantiomers on lethality, core temperature, and locomotor activity in singly housed and crowded mice.
Fantegrossi WE; Godlewski T; Karabenick RL; Stephens JM; Ullrich T; Rice KC; Woods JH
Psychopharmacology (Berl); 2003 Mar; 166(3):202-11. PubMed ID: 12563544
[TBL] [Abstract][Full Text] [Related]
4. Role of dopamine transporters in the behavioral effects of 3,4-methylenedioxymethamphetamine (MDMA) in nonhuman primates.
Fantegrossi WE; Bauzo RM; Manvich DM; Morales JC; Votaw JR; Goodman MM; Howell LL
Psychopharmacology (Berl); 2009 Aug; 205(2):337-47. PubMed ID: 19421742
[TBL] [Abstract][Full Text] [Related]
5. MDMA induced dopamine release in vivo: role of endogenous serotonin.
Koch S; Galloway MP
J Neural Transm (Vienna); 1997; 104(2-3):135-46. PubMed ID: 9203077
[TBL] [Abstract][Full Text] [Related]
6. The pharmacology of the acute hyperthermic response that follows administration of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') to rats.
Mechan AO; Esteban B; O'Shea E; Elliott JM; Colado MI; Green AR
Br J Pharmacol; 2002 Jan; 135(1):170-80. PubMed ID: 11786492
[TBL] [Abstract][Full Text] [Related]
7. 3,4-Methylenedioxymethamphetamine (MDMA, "ecstasy") and its stereoisomers as reinforcers in rhesus monkeys: serotonergic involvement.
Fantegrossi WE; Ullrich T; Rice KC; Woods JH; Winger G
Psychopharmacology (Berl); 2002 Jun; 161(4):356-64. PubMed ID: 12073162
[TBL] [Abstract][Full Text] [Related]
8. Discriminative stimulus effects of psychostimulants and hallucinogens in S(+)-3,4-methylenedioxymethamphetamine (MDMA) and R(-)-MDMA trained mice.
Murnane KS; Murai N; Howell LL; Fantegrossi WE
J Pharmacol Exp Ther; 2009 Nov; 331(2):717-23. PubMed ID: 19684254
[TBL] [Abstract][Full Text] [Related]
9. Reduced efficacy of fluoxetine following MDMA ("Ecstasy")-induced serotonin loss in rats.
Durkin S; Prendergast A; Harkin A
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1894-901. PubMed ID: 18824064
[TBL] [Abstract][Full Text] [Related]
10. Activation of protein kinase C (PKC) by 3,4-methylenedioxymethamphetamine (MDMA) occurs through the stimulation of serotonin receptors and transporter.
Kramer HK; Poblete JC; Azmitia EC
Neuropsychopharmacology; 1997 Sep; 17(3):117-29. PubMed ID: 9272479
[TBL] [Abstract][Full Text] [Related]
11. Serotonin (1A) receptor involvement in acute 3,4-methylenedioxymethamphetamine (MDMA) facilitation of social interaction in the rat.
Morley KC; Arnold JC; McGregor IS
Prog Neuropsychopharmacol Biol Psychiatry; 2005 Jun; 29(5):648-57. PubMed ID: 15908091
[TBL] [Abstract][Full Text] [Related]
12. Carrier-mediated release of serotonin by 3,4-methylenedioxymethamphetamine: implications for serotonin-dopamine interactions.
Gudelsky GA; Nash JF
J Neurochem; 1996 Jan; 66(1):243-9. PubMed ID: 8522960
[TBL] [Abstract][Full Text] [Related]
13. Effects of 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy') and para-methoxyamphetamine on striatal 5-HT when co-administered with moclobemide.
Freezer A; Salem A; Irvine RJ
Brain Res; 2005 Apr; 1041(1):48-55. PubMed ID: 15804499
[TBL] [Abstract][Full Text] [Related]
14. The selective 5-HT2A receptor antagonist M100907 enhances antidepressant-like behavioral effects of the SSRI fluoxetine.
Marek GJ; Martin-Ruiz R; Abo A; Artigas F
Neuropsychopharmacology; 2005 Dec; 30(12):2205-15. PubMed ID: 15886717
[TBL] [Abstract][Full Text] [Related]
15. Psychological and physiological effects of MDMA ("Ecstasy") after pretreatment with the 5-HT(2) antagonist ketanserin in healthy humans.
Liechti ME; Saur MR; Gamma A; Hell D; Vollenweider FX
Neuropsychopharmacology; 2000 Oct; 23(4):396-404. PubMed ID: 10989266
[TBL] [Abstract][Full Text] [Related]
16. The effects of fluoxetine on the subjective and physiological effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans.
Tancer M; Johanson CE
Psychopharmacology (Berl); 2007 Jan; 189(4):565-73. PubMed ID: 17047932
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological studies of the acute effects of (+)-3,4-methylenedioxymethamphetamine on locomotor activity: role of 5-HT(1B/1D) and 5-HT(2) receptors.
Bankson MG; Cunningham KA
Neuropsychopharmacology; 2002 Jan; 26(1):40-52. PubMed ID: 11751031
[TBL] [Abstract][Full Text] [Related]
18. 3,4-methylenedioxymethamphetamine (MDMA, ecstasy)-induced egr-1 mRNA in rat brain: pharmacological manipulation.
Shirayama Y; Hashimoto K; Iyo M; Watanabe K; Higuchi T; Minabe Y
Eur J Pharmacol; 2000 Aug; 402(3):215-22. PubMed ID: 10958887
[TBL] [Abstract][Full Text] [Related]
19. Serotonin synthesis inhibition reveals distinct mechanisms of action for MDMA and its enantiomers in the mouse.
Fantegrossi WE; Kiessel CL; De la Garza R; Woods JH
Psychopharmacology (Berl); 2005 Sep; 181(3):529-36. PubMed ID: 15983787
[TBL] [Abstract][Full Text] [Related]
20. Abnormal ACTH and prolactin responses to fenfluramine in rats exposed to single and multiple doses of MDMA.
Poland RE; Lutchmansingh P; McCracken JT; Zhao JP; Brammer GL; Grob CS; Boone KB; Pechnick RN
Psychopharmacology (Berl); 1997 Jun; 131(4):411-9. PubMed ID: 9226745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
